Journal of Clinical Oncology
Articles in this Issue
PD-L1 CPS ≥10 population subgroup analysis of KEYNOTE-412: Pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy for unresected locally advanced head and neck squamous cell carcinoma.
6063 Background: At the end-of-trial analysis of the randomized, double-blind, phase 3 KEYNOTE-412 trial (NCT03040999) in...
Clinicopathological characteristics and prognostic predictors in cervical clear cell adenocarcinoma: A multicenter cohort study.
e17505 Background: The clinicopathological profile and prognostic factors of cervical clear cell adenocarcinoma unrelated...
Updated results of benmelstobart combined with anlotinib and chemotherapy as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma: A single-arm, open-label phase II clinical trial.
6045 Background: Locally advanced head and neck squamous cell carcinoma (HNSCC) is characterized by high risks of local re...
A multicenter randomized phase II trial of topical betamethasone ointment for preventing severe chemoradiotherapy-induced oral mucositis in head and neck cancer.
12015 Background: Severe oral mucositis (OM) is a major unmet clinical problem during cisplatin-based chemoradiotherapy (C...
Evaluation of a large language model–generated after-visit summary from outpatient hematology/oncology progress notes.
e13692 Background: Oncology progress notes are technical and may be difficult for patients to interpret. We evaluated read...
Are patient-reported outcome measures valid across diverse cancer populations?: A review of psychometric evidence.
e23260 Background: Patient-reported outcome (PRO) assessments improve cancer care and health outcomes, including quality o...
Effect of first-line treatment of CLL/SLL with the all-oral combination of sonrotoclax (sonro) and zanubrutinib (zanu) on minimal residual disease (uMRD) rates, including in patients with del(17p)/TP53.
7043 Background: Oral, fixed-duration BTKi-BCL2i combinations are effective and convenient options for first-line treatmen...
Leptomeningeal carcinomatosis in pancreatic cancer: Clinical presentation, management, and outcomes—A systematic review.
e16431 Background: Leptomeningeal carcinomatosis (LMC) is a rare and devastating complication of advanced malignancies, oc...
Updated 5-year survival outcomes of short-course radiation followed by mFOLFOX-6 plus avelumab in locally advanced microsatellite-stable rectal adenocarcinoma: The Averectal phase II study.
3643 Background: Total neoadjuvant therapy (TNT) for microsatellite-stable (MSS) locally advanced rectal cancer consists o...
Response to neoadjuvant chemotherapy in both the breast and lymph nodes in patients with inflammatory breast cancer.
614 Background: Optimal outcomes in Inflammatory Breast Cancer (IBC) are achieved with trimodal therapy. We sought to eval...
Effect of a financial navigation intervention on financial toxicity among patients with breast cancer: A randomized controlled trial in China.
1520 Background: Financial toxicity (FT) is a common and burdensome consequence of breast cancer treatment, adversely affe...
Genomic and clinical correlates of belzutifan treatment in renal cell carcinoma (RCC): A retrospective analysis of 150 RCC patients.
4541 Background: Belzutifan is a hypoxia-inducible factor-2α (HIF-2α) inhibitor approved for RCC that targets a central dr...
Interpretable machine learning for prognostic survival prediction in mycosis fungoides: Model development and external validation.
e22612 Background: Mycosis fungoides (MF) has heterogeneous outcomes and persistent disparities, yet lacks widely adopted,...
Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: A multicenter, open-label phase 2 study.
4225 Background: The prognosis of locally advanced pancreatic cancer is dismal. The objective of the present study was to...
Clinical and radiographic responses to trastuzumab deruxtecan in molecularly defined ependymomas.
e14097 Background: Ependymomas are rare central nervous system (CNS) tumors lacking approved targeted therapies, and recur...
Local and state paid sick leave policies and timeliness of treatment initiation among working-age patients with early-stage breast cancer.
11064 Background: Local and state paid sick leave (PSL) mandates have been associated with increased use of preventive ser...
Geographic distribution of cancer treatment trials and population-level cancer outcomes in the U.S.
1556 Background: Access to cancer clinical trials varies geographically in the U.S., yet the relationship between trial av...
Efficacy and safety of zanubrutinib in Waldenström macroglobulinemia: A systematic review and meta-analysis of clinical trials.
e19569 Background: Bruton tyrosine kinase (BTK) inhibition has transformed the management of Waldenström macroglobulinemia...
AI-based assessment of tumor-infiltrating lymphocytes (TILs) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy versus chemo-immunotherapy.
e12583 Background: Most patients with early-stage TNBC receive neoadjuvant chemotherapy and immunotherapy, yet biomarkers...
Evidence supporting <i>RPS20</i> as a colorectal cancer susceptibility gene from a case-control MGPT study.
10617 Background: Ribosomal protein S20 ( RPS20 ) is increasingly included in colo...
Metabolic health and risk of early-onset cancers in obese young adults: Real-world insights from a large cohort study.
e22670 Background: Early-onset cancers, typically defined as malignancies occurring in adults under the age of 50, are an...
Pucotenlimab plus dose-intensified radiotherapy and chemotherapy for locally advanced rectal cancer: Preliminary results from a prospective, single-arm phase II trial (PUCRT).
e15635 Background: The neoadjuvant PD-1 inhibitors plus chemoradiotherapy (nCRT) has improved complete response (CR) rates...
A distinct immune–microbiome axis in early-onset colorectal cancer.
e15736 Background: The incidence of early-onset colorectal cancer (EOCRC; ≤50 years) is rising globally and is increasingl...
Phase 1 study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma.
11516 Background: Patients with advanced or recurrent synovial sarcoma (SS) have limited treatment options that can provid...
Predictors of tumor lysis syndrome in non-Hodgkin lymphoma hospitalizations.
11178 Background: Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency in non-Hodgkin lymphoma (NHL) cause...